Clinical trials: Early Initial Therapy
Chronic Myelogenous Leukemia
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
The purpose of this multicenter randomized study is to compare efficacy and safety of dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic phase (CP) chronic myeloid leukemia (CML)
- Trial name
- NCT03625388
- Testing
- Dasatinib
- Where
- 5 sites in Jordan, Lebanon and 2 more
- Volunteers
- 56 people
- Sponsor
- Hikma Pharmaceuticals LLC
Resistant Hypertension
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with…
- Trial name
- NCT06526858
- Testing
- HyperQureTM Renal Denervation (RDN) System:
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- DeepQure Inc.
Arthritis, Psoriatic
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration.
- Trial name
- FOREMOST (NCT03747939)
- Testing
- Apremilast (CC-10004)
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Breast Neoplasms
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive…
- Trial name
- NCT01239745
- Testing
- Aromasin
- Where
- 11 sites in Croatia, Estonia and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Relapsing Remitting Multiple Sclerosis
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same…
- Trial name
- EARLiMS (NCT01498887)
- Testing
- Fingolimod (FTY720)
- Where
- 47 sites in Australia, Spain
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa…
- Trial name
- ADOPTION (NCT04990284)
- Testing
- Opicapone, L-DOPA/DDCI
- Where
- 25 sites in Germany, Italy and 3 more
- Volunteers
- 106 people
- Sponsor
- Bial - Portela C S.A.
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Atrial Fibrillation
Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.
The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.
- Trial name
- NCT00408473
- Testing
- Flecainide
- Where
- 47 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 256 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
HIV
Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)
The AELIX-002 study aims to evaluate the safety and the immunogenicity of an heterologous prime-boost regimen with DNA.HTI, MVA.HTI and ChAdOx1.HTI in early diagnosed and treated HIV-1 positive individuals, males and…
- Trial name
- NCT03204617
- Testing
- DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM), At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Aelix Therapeutics
Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
The goal of this clinical investigation is to learn if a new type of radiotherapy works to treat pancreatic cancer that cannot be removed surgically.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable
- Trial name
- NCT07155850
- Testing
- Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 10 people
- Sponsor
- BetaGlue Therapeutics SpA
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical…
- Trial name
- START (NCT00461396)
- Testing
- Interferon-1beta (Betaseron, BAY86-5046)
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Bayer
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Diabetic Retinopathy
A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment
This study is open to adults with diabetic macular ischemia who have received laser treatment. The main purpose of this study is to find out whether people with diabetic macular ischemia can tolerate a medicine called BI 765128.
- Trial name
- PARTRIDGE (NCT04919499)
- Testing
- BI 765128
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Early Pregnancy Loss, Delayed Pregnancy Loss
CCT-102 or Expectant Management in Delayed Pregnancy Loss
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).
- Trial name
- MERMAID (NCT06121063)
- Testing
- CCT-102 A and CCT-102 B
- Where
- 15 sites in United States
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Conceptra Biosciences, LLC
Ankylosing Spondylitis, Axial Spondyloarthritis
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial…
- Trial name
- INFAST (NCT00844805)
- Testing
- Infliximab, Naproxen
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.
This is a post-authorization safety study (PASS) to describe the real-world use of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2D) in China.
- Trial name
- FIRST-2_CN (NCT07124039)
- Testing
- Finerenone (Kerendia, BAY948862)
- Where
- China
- Volunteers
- 6,537 people
- Sponsor
- Bayer
Urothelial Cancer
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Avelumab) in people with advanced urothelial (bladder) cancer (UC) whose disease hasn't worsened after receiving…
- Trial name
- NCT05366725
- Testing
- Avelumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 106 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
- Trial name
- NCT01298323
- Testing
- Patient outreach, Vandetanib
- Where
- 66 sites in Australia, Austria and 18 more
- Volunteers
- 205 people
- Sponsor
- Sanofi
Venous Insufficiency of Leg
Cook Venous Valve System for Treatment of Chronic Venous Insufficiency
The purpose of this study is to learn about the safety, efficacy and utility of a medical device called the Cook® Venous Valve System.
- Trial name
- NCT05883943
- Testing
- Cook® Venous Valve System
- Where
- 3 sites in Colombia
- Volunteers
- 4 people
- Sponsor
- MED Institute Inc.
Diabetes, Type I
A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes
Purpose: The purpose of the trial is to assess the safety profile of the study treatment and to evaluate its efficacy in terms of improvement in key diabetes management parameters, including insulin requirements and β-cell…
- Trial name
- IMMUNOSTEM (NCT06938334)
- Testing
- Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Altheia Science